October 17, 2011
1 min read
Save

Presenters identify new technology designed to improve diagnosis, measurement

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

BOSTON — Here at the Optometric Council on Refractive Technology meeting, held prior to Academy 2011 Boston, lecturers reported on advances in retinal imaging and wavefront aberrometry.

The Annidis RHA system combines multispectral imaging technology with multi-image software processing intended for early detection of age-related macular degeneration, diabetic retinopathy and glaucoma.

"This device takes different spectral photos of the eye, slicing through the retina and taking one wavelength after the next," David Geffen, OD, told attendees. "It goes right through the retina from the internal limiting membrane to the choroid.

"A typical fundus photo looks at a color photo of the eye through a narrow band of wavelengths. With this, we're getting a widespread use of topography of the retina so we can look at every slice of the eye," he continued. "It enhances our ability to detect disease earlier, especially with AMD."

Dr. Geffen said the Annidis RHA provides more information than an ocular coherence tomography scan and he has "found it to be a great asset."

The ORange intraoperative wavefront aberrometer by WaveTec Vision Systems is used during cataract surgery.

"It gives an accurate wavefront measurement while the patient is supine, getting ready to have the procedure done," Marc Bloomenstein, OD, reported. "We can use this to improve refractive outcomes.

"I would say 98.6% of patients in my practice are 20/20 or better after LASIK," he continued. "When we look at cataract surgery, the results aren't quite as good. ORange has been shown to improve outcomes. This takes a great lens and makes it a little bit better."

  • Disclosures: Drs. Bloomenstein and Geffen have no relevant financial disclosures.